These 5 stocks, based on recommendations from over 4,700 analysts, have all the top analysts buzzing right now.
The original article by Harriet Lefton has been edited for length (…) and clarity ([ ]) by munKNEE.com to provide a fast & easy read.
We have crunched the data and pinpointed five very compelling ‘strong buy’ stocks that are trending into 2018. You can see the average analyst price target and in green the upside percentage from the current share price. This represents a crucial indicator of the stock’s price potential over the next 12 months. To delve deeper simply click on the ticker. Let’s take a closer look now:
1. Micron (Nasdaq:MU)
Over the last five days, semiconductor hot stock Micron has received a whopping 13 buy ratings and just 2 hold ratings. Analysts believe (on average) that Micron has big upside potential of 30% from the current share price. Bear in mind, however, that MU has already doubled year-to-date.
Five-star Rajvindra Gill (he is ranked #43 out of over 4,700 analysts tracked by TipRanks)assigned a buy rating to MU with a very confident $76 price target on December 20 (72% upside)…
2. Aerie Pharma (Nasdaq:AERI)
Eye disease pharma Aerie Pharma has just received an early holiday gift from the FDA. The US regulatory body has approved Aerie’s lead product Rhopressa two months ahead of schedule. Aerie is now set to hire a 100-person strong sales force in preparation for launch in 2Q18.
Top Mizuho analyst Difei Yang believes the approval of Rhopressa reinforces her view that Aerie Pharmaceuticals is a strong takeout candidate. Yang has an $87 price target on the stock and a very strong AERI track record (86% success rate and 73% average return).
Overall AERI boasts 100% Street support with 7 buy ratings in the last three months. These analysts believe (on average) that AERI can leap a further 32% in the coming months.
3. Amazon (Nasdaq:AMZN)
Even with a share price of $1,168, we can see from the trending stocks page that analysts see Amazon spiking to $1,311. In fact, in the last three months this stock has received an eyebrow-raising 33 buy ratings vs just one hold rating.
The most recent rating comes from top RBC Capital analyst Mark Mahaney. He has just carried out a survey on Amazon’s intelligent personal assistant Alexa and he likes what he sees. “Following our third annual Alexa survey, we are more impressed with the traction of these devices and more convinced of their potential long-term impact. With tens of millions of users and 20K+ skills, we see Alexa’s value prop as becoming increasingly powerful as awareness and ownership ramp. We think AMZN could see $10-$11B in Alexa-related Rev by 2020.”
4. Smart Global Holdings Inc. (Nasdaq:SGH)
On the back of a strong beat and raise quarter, three analysts reiterated their buy ratings on specialty memory company SGH. Shares popped 10% on December 22 and analysts say shares can move another 25% from the current share price.
SGH CEO Iain MacKenzie commented that the company enjoyed ‘strength across the board.’ Revenue, gross margin, and earnings per share all exceeded the high ends of previous guidance. He now has even higher hopes for the coming quarters, due to Brazil and the improving global memory market. Indeed, current strength in Brazil is expected to continue throughout the year as the economy recovers.
5. Spark Therapeutics (Nasdaq:ONCE)
Spark Therapeutics is an interesting startup pharmaceutical company that develops gene therapies. The stock has just received a key FDA approval. ONCE has developed the first gene therapy to restore sight to individuals with a rare form of inherited blindness. Following the news, three analysts moved quickly to reiterate their ONCE buy ratings…
Overall this ‘Strong Buy’ stock has a bullish average analyst price target of $73 (38% upside potential)...